Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04142710
Other study ID # Medisinsk avstandsoppfølging
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 9, 2019
Est. completion date June 30, 2021

Study information

Verified date October 2021
Source University of Oslo
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Norwegian health authorities has initiated a three-year trial of telehealth solutions as part of the treatment of patients with chronic illness in the period 2018-2021. Within the trial, telehealth indicates that patients are followed-up outside health-care facilities using information and communication technologies (ICTs). Patients who are followed up using telehealth solutions can answer questions about their own health and/or perform measurements related to their health (e.g. blood pressure, blood glucose, oxygen measurement, weight) via a tablet according to a personalized schedule. The measurement values are transferred from the measuring devices to a tablet so that the users can easily see them and track their results over time. The results are also transmitted digitally to a follow-up service, a healthcare center with nurses, who contacts the patient when needed. The follow-up service provides medical support and guidance based on the patient's needs and planned follow-up, and will, in consultation with the user, evaluate whether the user should contact the general practitioner (GP) or emergency room. The study population of the trial includes users with comprehensive medical needs, with medium to high risk of worsening of their condition, hospitalization or increased need for health and care services. The evaluation includes three main parts: 1) An effect evaluation which is designed as a randomized control trial, 2) a cost-benefit analysis, and 3) a process evaluation which aims to provide recommendations for how to organize and implement telemedicine in clinical practice. The primary outcomes include physical and mental health state, patient experience and use of health services. The effect evaluation is designed as a pragmatic open label multi-center randomized control trial, with two parallel arms with 300 patients in each arm. Patients are recruited between February 2019 and June 2020.


Recruitment information / eligibility

Status Completed
Enrollment 732
Est. completion date June 30, 2021
Est. primary completion date June 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - The patient has a considerable disease burden and comprehensive medical needs - The patient has a chronic disease - The patient has medium to high risk of worsening of their condition, hospitalization or increased need for health and care services - The patient has a high consumption of healthcare services - The patient has a reduced level of function - The patient is motivated to use telehealth solutions - The patient is likely to benefit from the use of telehealth solutions Exclusion Criteria: - The patient is not competent to consent - The patient is unable to handle the tablet and the measuring equipment to be used - The patient has a substance abuse

Study Design


Intervention

Device:
Telemedicine: tablet and possibly tools to perform measurements
Users of telemedicine can answer simple questions about their health condition and/or perform measurements related to their health (e.g., blood pressure, blood sugar, oxygen saturation, weight) via a tablet or a similar device. The results are transferred from the measuring devices to the tablet so that users can easily see them and track their own results over time. The results are transmitted digitally to a follow-up service. The follow-up service contacts the patient in case of signs of deterioration or when measurements lie outside what is normal values for the individual. The follow-up service provides medical support and guidance based on the patient's needs and plan for follow-up, and will, in consultation with the patient, assess whether this should contact their GP/emergency room.

Locations

Country Name City State
Norway Bodø municipality Bodø
Norway Eid municipality Eidfjord
Norway Ullensaker municipality Jessheim
Norway Kristiansand municipality Kristiansand
Norway Larvik municipality Larvik
Norway Gamle Oslo district, Oslo Oslo
Norway Grünerløkka district, Oslo Oslo
Norway Sagene ditrict, Oslo Oslo
Norway St.Hanshaugen district, Oslo Oslo

Sponsors (4)

Lead Sponsor Collaborator
University of Oslo Norsk Gallup Institutt AS, Norwegian Centre for Rural Medicine, Oslo Economics

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean change in health-related quality of life (EuroQol 5 Dimensions 5 Levels (EQ-5D-5L)) from baseline at 6 months Patient's assessment of her health-related quality of life using the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) questionnaire. The scale goes from 0 to 1 where higher scores mean a better outcome. Measured as change from baseline to 6 months after inclusion
Primary Mean change in health-related quality of life (EuroQol 5 Dimensions 5 Levels (EQ-5D-5L)) from baseline at 12 months Patient's assessment of her health-related quality of life using the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) questionnaire. The scale goes from 0 to 1 where higher scores mean a better outcome. Measured as change from baseline to 12 months after inclusion
Primary Mean change in health-related quality of life (EuroQol 5 Dimensions 5 Levels (EQ-5D-5L)) from baseline at 18 months Patient's assessment of her health-related quality of life using the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) questionnaire. The scale goes from 0 to 1 where higher scores mean a better outcome. Measured as change from baseline to 18 months after inclusion
Primary Mean change in health-related quality of life (Visual Analogue Scale (VAS)) from baseline at 6 months Patient's assessment of her health-related quality of life using Visual Analogue Scale (VAS). The scale goes from 0 to 100 where higher scores mean a better outcome. Measured as change from baseline to 6 months after inclusion
Primary Mean change in health-related quality of life (Visual Analogue Scale (VAS)) from baseline at 12 months Patient's assessment of her health-related quality of life using Visual Analogue Scale (VAS). The scale goes from 0 to 100 where higher scores mean a better outcome. Measured as change from baseline to 12 months after inclusion
Primary Mean change in health-related quality of life (Visual Analogue Scale (VAS)) from baseline at 18 months Patient's assessment of her health-related quality of life using Visual Analogue Scale (VAS). The scale goes from 0 to 100 where higher scores mean a better outcome. Measured as change from baseline to 18 months after inclusion
Primary Mean change in overall satisfaction with treatment and follow-up from baseline at 6 months Patients are asked to assess their overall satisfaction with their health care services: "To what extent are you satisfied with the follow-up of your health?". Answers on a four point scale ranging from "Not satisfied at all" to "Very satisfied" Measured as change from baseline to 6 months after inclusion
Primary Mean change in overall satisfaction with treatment and follow-up from baseline at 12 months Patients are asked to assess their overall satisfaction with their health care services: "To what extent are you satisfied with the follow-up of your health?". Answers on a four point scale ranging from "Not satisfied at all" to "Very satisfied" Measured as change from baseline to 12 months after inclusion
Primary Mean change in overall satisfaction with treatment and follow-up from baseline at 18 months Patients are asked to assess their overall satisfaction with their health care services: "To what extent are you satisfied with the follow-up of your health?". Answers on a four point scale ranging from "Not satisfied at all" to "Very satisfied" Measured as change from baseline to 18 months after inclusion
Primary Change in yearly health and care cost per person from baseline at 12 months The total cost of health and care services per patient is calculated by combining information on the use of health and care services with information about private and public costs of health and care services. Yearly health and care cost per person at baseline is defined as the yearly cost 365 days before inclusion. Similarly, the health and care cost at 12 months in defined as the total cost in the first year after inclusion. The change in mean is the primary outcome measure. Other changes, such as distributional changes, may be of interest. Yearly health and care cost per person is calculated at baseline and at 12 months after inclusion.
Secondary Mean change in sleep quality from baseline at 6 months Participants are asked the following question: "If you think about the last 7 days, to what degree have you experienced the following a) had problems sleeping at night b) had problems sleeping too much?" Answers on a four point scale ranging from "Not at all" to "To a very large extent". Measured as change from baseline to 6 months after inclusion
Secondary Mean change in sleep quality from baseline at 12 months Participants are asked the following question: "If you think about the last 7 days, to what degree have you experienced the following a) had problems sleeping at night b) had problems sleeping too much?" Answers on a four point scale ranging from "Not at all" to "To a very large extent". Measured as change from baseline to 12 months after inclusion
Secondary Mean change in sleep quality from baseline at 18 months Participants are asked the following question: "If you think about the last 7 days, to what degree have you experienced the following a) had problems sleeping at night b) had problems sleeping too much?" Answers on a four point scale ranging from "Not at all" to "To a very large extent". Measured as change from baseline to 18 months after inclusion
Secondary Mean change in patients' sense of control over their health situation from baseline at 6 months Participants are asked the following question: "To what extent do you feel that you have control over your health situation?" Answers on a four point scale ranging from "Not at all" to "To a very large extent". Measured as change from baseline to 6 months after inclusion
Secondary Mean change in patients' sense of control over their health situation from baseline at 12 months Participants are asked the following question: "To what extent do you feel that you have control over your health situation?" Answers on a four point scale ranging from "Not at all" to "To a very large extent". Measured as change from baseline to 12 months after inclusion
Secondary Mean change in patients' sense of control over their health situation from baseline at 18 months Participants are asked the following question: "To what extent do you feel that you have control over your health situation?" Answers on a four point scale ranging from "Not at all" to "To a very large extent". Measured as change from baseline to 18 months after inclusion
Secondary Mean change in patients' satisfaction with involvement of the GP from baseline at 6 months Patients answer the question "To what extent do you experience your GP is sufficiently involved in the follow-up of your health?" Answers are reported on a four point scale: "Not at all" to "To a very large extent". Measured as change from baseline to 6 months after inclusion
Secondary Mean change in patients' satisfaction with involvement of the GP from baseline at 12 months Patients answer the question "To what extent do you experience your GP is sufficiently involved in the follow-up of your health?" Answers are reported on a four point scale: "Not at all" to "To a very large extent". Measured as change from baseline to 12 months after inclusion
Secondary Mean change in patients' satisfaction with involvement of the GP from baseline at 18 months Patients answer the question "To what extent do you experience your GP is sufficiently involved in the follow-up of your health?" Answers are reported on a four point scale: "Not at all" to "To a very large extent". Measured as change from baseline to 18 months after inclusion
Secondary Mean change in patients' sense of user involvement from baseline at 6 months Patients are asked "To what extent do you experience that you have opportunity to contribute to your own treatment?" Answers are reported on a four point scale: "Not at all" to "To a very large extent". Measured as change from baseline to 6 months after inclusion
Secondary Mean change in patients' sense of user involvement from baseline at 12 months Patients are asked "To what extent do you experience that you have opportunity to contribute to your own treatment?" Answers are reported on a four point scale: "Not at all" to "To a very large extent". Measured as change from baseline to 12 months after inclusion
Secondary Mean change in patients' sense of user involvement from baseline at 18 months Patients are asked "To what extent do you experience that you have opportunity to contribute to your own treatment?" Answers are reported on a four point scale: "Not at all" to "To a very large extent". Measured as change from baseline to 18 months after inclusion
Secondary Mean change in the patients' number of appointments with the GP services from baseline at 12 months Yearly number of appointments with the GP services at baseline is defined as the yearly use 365 days before inclusion. Similarly, the yearly number of appointments with of the GP services at 12 months is defined as the use in the first year after inclusion. The mean change is the primary outcome measure. Yearly use of the GP services is calculated at baseline and at 12 months after inclusion.
Secondary Mean change in the patients' number of outpatient visits from baseline at 12 months Yearly number of outpatient visits at baseline is defined as the yearly use 365 days before inclusion. Similarly, the yearly number of outpatient visits at 12 months is defined as the use in the first year after inclusion. The mean change is the primary outcome measure. Yearly number of outpatient visits is calculated at baseline and at 12 months after inclusion.
Secondary Mean change in the patients' number of inpatient visits from baseline at 12 months Yearly number of inpatient visits at baseline is defined as the yearly cost 365 days before inclusion. Similarly, the yearly number of inpatient visits at 12 months is defined as the use in the first year after inclusion. The mean change is the primary outcome measure. Yearly number of inpatient visits is calculated at baseline and at 12 months after inclusion.
Secondary Mean change in the patients' duration of inpatient visits from baseline at 12 months Total duration of inpatient visits at baseline is defined as the total duration of inpatient visits 365 days before inclusion. Similarly, the total duration of inpatient visits at 12 months is defined as the total duration in the first year after inclusion. The mean change is the primary outcome measure. Total duration of inpatient visits is calculated at baseline and at 12 months after inclusion.
Secondary Mean change in the patients' number of emergency room visits from baseline at 12 months Yearly number of emergency room visits at baseline is defined as the yearly use 365 days before inclusion. Similarly, the yearly number of emergency room visits at 12 months is defined as the yearly use in the first year after inclusion. The mean change is the primary outcome measure. Yearly number of emergency room visits is calculated at baseline and at 12 months after inclusion.
Secondary Mean change in the patients' number of home nursing visits from baseline at 6 months Use of home nursing visits before inclusion is measured as the total number of home nursing visits 30 to 60 days prior to inclusion. Use at 6 months is measured as the total number of home nursing visits 150 to 180 days after inclusion. Use of home nursing visits is measured one month prior to inclusion and 6 months after inclusion.
Secondary Mean change in the patients' number of home nursing visits from baseline at 12 months Use of home nursing visits before inclusion is measured as the total number of home nursing visits 30 to 60 days prior to inclusion. Use at 12 months is measured as the total number of home nursing visits 335 to 365 days after inclusion. Use of home nursing visits is measured one month prior to inclusion and 12 months after inclusion.
Secondary Mean change in the patients' number of home nursing visits from baseline at 18 months Use of home nursing visits before inclusion is measured as the total number of home nursing visits 30 to 60 days prior to inclusion. Use at 18 months is measured as the total number of home nursing visits 515 to 545 days after inclusion. Use of home nursing visits is measured one month prior to inclusion and 18 months after inclusion.
Secondary Mean change in the patients' duration of home nursing visits from baseline at 6 months Total duration of home nursing visits before inclusion is measured as the total duration of home nursing visits 30 to 60 days prior to inclusion. Total duration at 6 months is measured as the total duration of home nursing visits 150 to 180 days after inclusion. Total duration of home nursing visits is measured one month prior to inclusion and 6 months after inclusion.
Secondary Mean change in the patients' duration of home nursing visits from baseline at 12 months Total duration of home nursing visits before inclusion is measured as the total duration of home nursing visits 30 to 60 days prior to inclusion. Total duration at 12 months is measured as the total duration of home nursing visits 335 to 365 days after inclusion. Total duration of home nursing visits is measured one month prior to inclusion and 12 months after inclusion.
Secondary Mean change in the patients' duration of home nursing visits from baseline at 18 months Total duration of home nursing visits before inclusion is measured as the total duration of home nursing visits 30 to 60 days prior to inclusion. Total duration at 18 months is measured as the total duration of home nursing visits 515 to 545 days after inclusion. Total duration of home nursing visits is measured one month prior to inclusion and 18 months after inclusion.
Secondary Mean change in the patients' number of municipal emergency day care unit visits from baseline at 6 months Use of municipal emergency day care unit visits before inclusion is measured as the total number of municipal emergency day care unit visits 30 to 60 days prior to inclusion. Use at 6 months is measured as the total number of municipal emergency day care unit visits 150 to 180 days after inclusion. Use of municipal emergency day care unit visits is measured one month prior to inclusion and 6 months after inclusion.
Secondary Mean change in the patients' number of municipal emergency day care unit visits from baseline at 12 months Use of municipal emergency day care unit visits before inclusion is measured as the total number of municipal emergency day care unit visits 30 to 60 days prior to inclusion. Use at 12 months is measured as the total number of municipal emergency day care unit visits 335 to 365 days after inclusion. Use of municipal emergency day care unit visits is measured one month prior to inclusion and 12 months after inclusion.
Secondary Mean change in the patients' number of municipal emergency day care unit visits from baseline at 18 months Use of municipal emergency day care unit visits before inclusion is measured as the total number of municipal emergency day care unit visits 30 to 60 days prior to inclusion. Use at 18 months is measured as the total number of municipal emergency day care unit visits 515 to 545 days after inclusion. Use of municipal emergency day care unit visits is measured one month prior to inclusion and 18 months after inclusion.
Secondary Mean change in the patients' duration of municipal emergency day care unit visits from baseline at 6 months Total duration of municipal emergency day care unit visits before inclusion is measured as the total duration of municipal emergency day care unit visits 30 to 60 days prior to inclusion. Total duration at 6 months is measured as the total duration of municipal emergency day care unit visits 150 to 180 days after inclusion. Total duration of municipal emergency day care unit visits is measured one month prior to inclusion and 6 months after inclusion.
Secondary Mean change in the patients' duration of municipal emergency day care unit visits from baseline at 12 months Total duration of municipal emergency day care unit visits before inclusion is measured as the total duration of municipal emergency day care unit visits 30 to 60 days prior to inclusion. Total duration at 12 months is measured as the total duration of municipal emergency day care unit visits 335 to 365 days after inclusion. Total duration of municipal emergency day care unit visits is measured one month prior to inclusion and 12 months after inclusion.
Secondary Mean change in the patients' duration of municipal emergency day care unit visits from baseline at 18 months Total duration of municipal emergency day care unit visits before inclusion is measured as the total duration of municipal emergency day care unit visits 30 to 60 days prior to inclusion. Total duration at 18 months is measured as the total duration of municipal emergency day care unit visits 515 to 545 days after inclusion. Total duration of municipal emergency day care unit visits is measured one month prior to inclusion and 18 months after inclusion.
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases